RPODUCT
INFORMATION
Respiratory Health Supporting Individually Recognized Ingredient.
A functional ingredient acknowledged by the KFDA
Premium, 100% plant-based ingredient extracted from the
trational health material 'Rosa laevigata'.
PP-017 holds two domestic patents!
Proven efficacy with three SCI-level research paper published!
Category
Functional Food
Model
PP-017
Indication
Respiratory
Purchase
Online shop
Kyung Hee University Oriental Medicine Hospital
NeurorescueX - a leading preventive medication
for the recurrence of ischemic stroke
Kyung Hee University Oriental Medicine Hospital's leading
preventive medication for the recurrence of ischemic stroke
Prescribed as a preventive medication for ischemic stroke
for 20 years since its development in 2002.
From January 2019 to December 2021 (over 2 years)
a total of approximately 4,500 outpatient prescriptions and
14,100 inpatient prescriptions were made.
HH333
Category
Medicine
Model
HH333
Indication
Ischemic stroke
Purchase
Online shop
Kyung Hee University Korean Medicine Hospital's Representative
medication for the prevention of recurrent ischemic stroke
From 2019 to 2021, over 4,500 outpatient cases and approximately
14,100 inpatient cases were recorded
two-year retrospective cohort study show a 2.0% recurrence rate for stroke
five-year retrospective cohort study show a recurrence rate of 6.2%
The recurrence rate decreased by more than four times compared to
conventional antiplatelet therapy (8.2%).
Aspirin has no benefit in preventing
the recurrence of ischemic stroke
Antiplatelet agents and anticoagulants, traditionally used for the prevention of ischemic stroke,
have side effects that increase the tendency to bleed.
Patients with small vessel cerebral infarction may have an accompanying possibility of intracerebral microbleeds.
Issues regarding efficacy and safety.
Stroke and Brain
Disease Center Faculty
Researched and developed by the faculty
of the Stroke and Brain Disease Center
A business agreement between Panacura Inc.
and Kyung Hee University Oriental Medicine Hospital
Efficacy and safety proven
through over 20 years of prescriptions
2-year retrospective
cohort study
Recurrence rate of ischemic stroke: 2.0%
Control group (antiplatelet agents)
Recurrence rate of ischemic stroke: 8.2%
Compared to the control group
Fourfold reduction in recurrence rate
Subjects: 356 patients with ischemic stroke
Dosage: NRX 600mg/day4o
Study Design: Patient-control study, open-label trial4o
5-year retrospective
cohort study
Third-year recurrence rate of ischemic stroke
: 2.6 %
Fourth-year recurrence rate of ischemic stroke
: 4.7 %
Fifth-year recurrence rate of ischemic stroke
: 6.2 %
Existing antiplatelet agents
24-72 months recurrence rate
: 6.1% to a maximum of 12.4%
Subjects: 400 patients with ischemic stroke
Dosage: Cheonghyeoldan 600mg/day
Study Design: Retrospective cohort observational study
2-year retrospective
cohort study
Recurrence rate of ischemic stroke: 2.0%
Control group (antiplatelet agents)
Recurrence rate of ischemic stroke: 8.2%
Compared to the control group
Fourfold reduction in recurrence rate
HH333
Kyung Hee University Oriental Medicine Hospital
NeurorescueX - a leading preventive medication
for the recurrence of ischemic stroke
Kyung Hee University Oriental Medicine Hospital's leading
preventive medication for the recurrence of ischemic stroke
Prescribed as a preventive medication for ischemic stroke
for 20 years since its development in 2002.
From January 2019 to December 2021 (over 2 years)
a total of approximately 4,500 outpatient prescriptions and
14,100 inpatient prescriptions were made.
Stroke and Brain
Disease Center Faculty
Researched and developed by the faculty
of the Stroke and Brain Disease Center
A business agreement between Panacura Inc.
and Kyung Hee University Oriental Medicine Hospital
Efficacy and safety proven
through over 20 years of prescriptions
5-year retrospective
cohort study
Third-year recurrence rate of ischemic stroke: 2.6 %
Fourth-year recurrence rate of ischemic stroke : 4.7 %
Fifth-year recurrence rate of ischemic stroke: 6.2 %
Existing antiplatelet agents
24-72 months recurrence rate
: 6.1% to a maximum of 12.4%
Aspirin has no benefit in preventing
the recurrence of ischemic stroke
Antiplatelet agents and anticoagulants,
traditionally used for the prevention of ischemic stroke,
have side effects that increase the tendency to bleed.
Issues regarding efficacy and safety.
pRODUCT
INFORMATION
pRODUCT
INFORMATION
Kyung Hee University Korean Medicine Hospital's Representative medication for the prevention of recurrent ischemic stroke
From 2019 to 2021, 4,500 outpatient cases and
approximately 14,100 inpatient cases were recorded
two-year retrospective cohort study show a 2.0
recurrence rate for stroke
The recurrence rate decreased by more than
four times compared to conventional
antiplatelet therapy (8.2%).
five-year cohort study show a recurrence rate of 6.2%
010-2162-6079
Tel.
support@pana-cura.com
강원특별자치도 춘천시 소양강로32
춘천바이오산업단지 201-3호
Address
강원특별자치도 춘천시 소양강로32 춘천바이오산업단지 201-3호
010-2162-6079
Tel.
Address
support@pana-cura.com